Hypocalcemia
Drug research and approvals for hypocalcemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 10 studies of hypocalcemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 2 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 10
- Trials authorized in Canada: 1
- FDA orphan approvals: 2
- EU medicines: 0
- NIRAF-Guided Parathyroid Identification During ThyroidectomyNCT07617584 · Not applicable · Ss. Cyril and Methodius University of Skopje · starts Sep 1, 2026
- Postoperative Hypocalcemia After ThyroidectomyNCT07428057 · Not reported · Minia University · starts Jan 1, 2014
- Comparing PTeye-assisted Versus Conventional Total ThyroidectomyNCT07416149 · Not applicable · The University of Hong Kong · starts Sep 16, 2025
- Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants With Autosomal Dominant Hypocalcemia Type…NCT07080385 · Phase 2 / Phase 3 · Calcilytix Therapeutics, Inc., a BridgeBio company · starts Jan 30, 2026
- Quantitative Intra-operative Assessment of Parathyroid Perfusion Using Indocyanine Green (ICG) Fluorescence ImagingNCT07010341 · Not reported · Fujian Medical University · starts May 1, 2025
- National Registry of Rare Kidney DiseasesNCT06065852 · Not reported · UK Kidney Association · starts Nov 6, 2009
- Registry for Hypoparathyroidism WuerzburgNCT05585593 · Not reported · University of Wuerzburg · starts Oct 18, 2017
- Usefulness of ICG Angiography-Guided Thyroidectomy for Preserving Parathyroid FunctionNCT05573828 · Not applicable · Hospital Universitari de Bellvitge · starts Oct 11, 2022
- Contribution of ICG Angiography in the Detection of Parathyroids and the Prevention of Hypoparathyroidism Post Total…NCT04785443 · Phase 3 · University Hospital, Brest · starts Jun 22, 2021
Approved 2
- CalcitriolVitamin D receptor agonist
- Parathyroid hormoneParathyroid hormone receptor agonist
Phase 3 2
- Encaleret
- ErgocalciferolVitamin D receptor agonist
Phase 2 3
- ParicalcitolVitamin D receptor agonist
- DexamethasoneGlucocorticoid receptor agonist
- SB-423562
How its trials ended
71 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 10 whose ending is known, 60% met their primary endpoint, 10% missed it and 30% stopped early.
- Completed, result not reported2535%
- Status unknown2028%
- Ongoing1623%
- Met its primary endpoint68%
- Missed its primary endpoint11%
- Stopped: lack of efficacy11%
- Stopped: enrollment or feasibility11%
- Stopped: other or unclear11%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Nov 17, 2022 | Calibrate: a phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret compared to standard of care in participants with autosomal…Encaleret (CLTX-305) | Calcilytix Therapeutics Inc | Ongoing |
| Jan 23, 2015 | NatparaAn adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism | Takeda Pharmaceuticals U.S.A., Inc. | Approved |
| Dec 23, 1987 | ParatharDiagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due… | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Approved |
| Nov 24, 2020 | Encaleret sulfateTreatment for autosomal dominant hypocalcemia (including ADH type 1 and ADH type 2) | Calcilytix Therapeutics, Inc. a BridgeBio Company | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA